The 5-week pilot tests DehydraTECH semaglutide tablets and capsules with SNAC. Lexaria expects the last group to finish dosing in mid-November.
Recap by typeshit. Full story at Yahoo Finance.
The REDEFINE 1 data covered 2,309 women, with placebo at 3%. In the REDEFINE 4 head-to-head, tirzepatide matched or slightly beat it.
Superpower says the drug carries radiation straight to cancer cells and cites a phase 3 trial showing a 79% lower risk of progression or death. A 14-part thread.
Australian experts note about half a million people there use GLP-1 drugs for diabetes alone, and lay out what new users should keep in mind about nutrition.
A herpetology-themed clip from PBS points to reptiles as part of the story behind today's GLP-1 medications. Short and light, but a fun bit of history.
Monthly units climbed from 114,000 in February to 434,000 in September, and sales value rose from ₹48 cr to ₹113 cr as doctors report wider access.
The orexin agonist, FDA approved in August, is being studied for ADHD and Parkinson's fatigue. Takeda's R&D head compares its reach to GLP-1 drugs, though data is early.
Loading…